Showing results (91-100 of 307) with videos related to
Sort By:
Pageof 31
Nature Reviews. Drug Discovery|October 13, 2018
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugsDelphine Charvin, Rossella Medori, Robert A Hauser, et al.Nature Reviews. Drug Discovery|September 29, 2018
Therapeutic strategies for Parkinson disease: beyond dopaminergic drugsDelphine Charvin, Rossella Medori, Robert A Hauser, et al.Expert Review of Neurotherapeutics|December 22, 2006
Nonmotor symptoms of Parkinson's diseaseTheresa A Zesiewicz, Kelly L Sullivan, Robert A HauserThe Neurologist|September 1, 2004
Essential tremor. Epidemiology, diagnosis, and treatmentKelly L Sullivan, Robert A Hauser, Theresa A ZesiewiczPostgraduate Medicine|June 4, 2021
On demand therapy for Parkinson's disease patients: Opportunities and choicesRobert A Hauser, Peter A LeWitt, Cynthia L ComellaParkinson'S Disease|July 4, 2012
A(2A) Receptor Antagonism and Dyskinesia in Parkinson's DiseaseMicaela Morelli, Fabio Blandini, Nicola Simola, et al.Journal of Parkinson'S Disease|June 23, 2020
Carbidopa and Levodopa Extended Release Capsules in Patients with and without Troublesome and Non-Troublesome DyskinesiaRobert A Hauser, Leonid Zeitlin, Stanley Fisher, et al.Neuropsychiatric Disease and Treatment|June 3, 2021
Assessment of the Impact of Tardive Dyskinesia in Clinical Practice: Consensus Panel RecommendationsRichard Jackson, Matthew N Brams, Leslie Citrome, et al.Expert Review of Neurotherapeutics|January 28, 2021
Istradefylline - a first generation adenosine A2A antagonist for the treatment of Parkinson's diseasePeter Jenner, Akihisa Mori, Stephen D Aradi, et al.Movement Disorders Clinical Practice|January 15, 2019
Integrated Analysis of Droxidopa for the Treatment of Neurogenic Orthostatic Hypotension in Patients with Parkinson DiseaseRobert A Hauser, Italo Biaggioni, L Arthur Hewitt, et al.Pageof 31